- Comprises newly Published Process Patents for Marketed Pharmaceutical Drugs published as CA, DE, EP, FR, GB, US and WO Patent Specifications and others as found since 1 January, 2010, at least.
- Up-to-date – Newly published Process Patent records are added to the Database within a month of publication.
- Drug Process Patent History for specific drugs will be added on an ongoing basis, eg Atorvastatin.
- The Database is fully Text and Structure Searchable
• Monthly Subscription: First user – £120 / month with a free trial of 1 month and a sign-up fee of £9.99 includes Quarterly Reports
• Annual Subscription: First user – £1200 / year with a free trial of 1 month and a sign-up fee of £9.99 includes Quarterly Reports
Reports comprise records taken from the Online Database. Report Types:-
- Quarterly Reports published every quarter showing the latest records added to the database in text-searchable PDFs. Quarterly Reports have been published since 1 January 2017. 4-Weekly Reports were published from 1 January 2014 to 1 January 2017. Back issues are available.
- Bespoke Reports from the Database using selected criteria, e.g. by Drug, Patentee etc. (contact us for prices)
• Annual Subscription: First user – £590 / year with a sign-up fee of £5.99
• Additional Users/Institutional Users – please contact us.
A Basic Patent Status is included in each record to briefly indicate the progress of the Patent Application. Many Process Patents do not proceed to Grant.
Due to the number of languages encountered, some countries will not be covered – however these will be included when an in-house readable language patent family equivalent emerges (eg a published EP patent specification equivalent to a CN, JP, KR etc patent specification).
Due to the prevalence of equivalent patent specifications in patent families and in an attempt to exclude repetitions, the Online Database will only include NEW patent specifications, i.e. those without previously published family equivalents. Equivalent patent family specifications may be obtained from free or commercial patent databases.
As a Marketed Pharmaceutical Drug approaches its Product Patent term expiry (including SPCs &c), numerous Process patents are filed in efforts to enhance the profitability of commercial synthesis, especially for when the Marketed Drug goes Generic. However, the FDA, for example, does not list Process Patents and these are often lost within a plethora of other pharmaceutical patents (new drugs, compositions &c) in high cost patent databases.
View PDF File